PROMISE seeks to learn more about the role genes can play in improving outcomes for prostate cancer patients. Specifically, PROMISE research will examine how information about particular genetic profiles can:
- Influence the susceptibility of men to prostate cancer
- Impact the effectiveness of existing treatments
- Improve guidance for different and/or new treatment options
- suggest precise areas to explore for new discoveries.
The specific goal for this PROMISE research study is to show how specific inherited genetic factors or mutations (also called pathogenic variants in genes) of patients with prostate cancer can affect outcomes and/or treatment for those patients. A pathogenic variant is a genetic alteration that increases an individual’s susceptibility or predisposition to a certain disease or disorder such as cancer. When these variants (or mutations) are inherited, development of cancer may be more likely, but not certain.